Molecular Therapy: Nucleic Acids (Dec 2021)

Suppression of endothelial miR-22 mediates non-small cell lung cancer cell-induced angiogenesis

  • Yuan Gu,
  • Gianni Pais,
  • Vivien Becker,
  • Christina Körbel,
  • Emmanuel Ampofo,
  • Elke Ebert,
  • Johannes Hohneck,
  • Nicole Ludwig,
  • Eckart Meese,
  • Rainer M. Bohle,
  • Yingjun Zhao,
  • Michael D. Menger,
  • Matthias W. Laschke

Journal volume & issue
Vol. 26
pp. 849 – 864

Abstract

Read online

MicroRNAs (miRNAs) expressed in endothelial cells (ECs) are powerful regulators of angiogenesis, which is essential for tumor growth and metastasis. Here, we demonstrated that miR-22 is preferentially and highly expressed in ECs, while its endothelial level is significantly downregulated in human non-small cell lung cancer (NSCLC) tissues when compared to matched nontumor lung tissues. This reduction of endothelial miR-22 is possibly induced by NSCLC cell-secreted interleukin-1β and subsequently activated transcription factor nuclear factor-κB. Endothelial miR-22 functions as a potent angiogenesis inhibitor that inhibits all of the key angiogenic activities of ECs and consequently NSCLC growth through directly targeting sirtuin 1 and fibroblast growth factor receptor 1 in ECs, leading to inactivation of AKT/mammalian target of rapamycin signaling. These findings provide insight into the molecular mechanisms of NSCLC angiogenesis and indicate that endothelial miR-22 represents a potential target for the future antiangiogenic treatment of NSCLC.

Keywords